Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Cancer - 1 Apr 2018

Ross Jeffrey S, Fakih Marwan, Ali Siraj M, Elvin Julia A, Schrock Alexa B, Suh James, Vergilio Jo-Anne, Ramkissoon Shakti, Severson Eric, Daniel Sugganth, Fabrizio David, Frampton Garrett, Sun James, Miller Vincent A, Stephens Philip J, Gay Laurie M

Abstract excerpt

BACKGROUND: In contrast to lung cancer, few precision treatments are available for colorectal cancer (CRC). One rapidly emerging treatment target in CRC is ERBB2 (human epidermal growth factor receptor 2 [HER2]). Oncogenic alterations in HER2, or its dimerization partner HER3, can underlie sensitivity to HER2-targeted therapies. METHODS: In this study, 8887 CRC cases were evaluated by comprehensive genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Gene Amplification

Share to Microsatellite Instability

Share to Molecular Targeted Therapy

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Source

Open in PubMed Open full text

Identifiers

PMID: 29338072
DOI: 10.1002/cncr.31125
PMCID: PMC5900732

Genes

ERBB2
ERBB3
KRAS
MTOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.PMID 29338072Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.Semantic proximity Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.Semantic proximity Read ↗

Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis.Semantic proximity Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma.Semantic proximity Read ↗

Genomic alterations of ERBB receptors in cancer: clinical implicationsSemantic proximity Read ↗

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.Semantic proximity Read ↗

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.Semantic proximity Read ↗

ERBB2 emerges as a new target for colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.